Zyngenia, Inc., a biopharmaceutical company developing Zybodies(TM), next-generation multi-specific antibody-based drugs in oncology and immunology, announced today that it has…
Rockville-based Human Genome Sciences Inc., which last week rejected an unsolicited $2.6 billion acquisition offer by GlaxoSmithKline PLC, reported higher…